drugset / Trial / NCT02151149

Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly

NCT02151149

Phase 4 Completed 143 enrolled Celgene Corporation
RandomizedParallel-groupOpen-labelTreatment

Summary

Study comparing two regimens of nab-paclitaxel and carboplatin combination in elderly subjects (≥ 70 years old) with advanced NSCLC

Timeline

Start
2014-06-09
Primary completion
2017-07-14
Completion
2017-07-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule 6 unknown Intravenous
Subject Paclitaxel Small molecule 100 mg/m2 Intravenous